Viatris (VTRS) is back in focus after raising its 2026 earnings guidance alongside second quarter results that showed higher sales and revenue year on year, as well as a return to net profitability for the first half.

At a share price of US$16.23, Viatris has seen some short term softness with a 1 month share price return of 2.7% and a 3 month share price return of 1.5%. At the same time, the year to date share price return of 30.26% sits alongside a 1 year total shareholder return of 59% and a 3 year total shareholder return of 64.04%, which suggests recent earnings guidance, dividends and the ongoing buyback are being weighed against earlier market caution.

If Viatris’s mix of earnings guidance, dividends and buybacks has your attention, this could be a good moment to widen your watchlist with 44 healthcare AI stocks

Viatris now trades at a discount to both analyst targets and an intrinsic value estimate, even after the recent move on guidance. Is the market still too cautious, or is that gap exactly what the current risks warrant?

Most Popular Narrative: 12.3% Undervalued

At a last close of $16.23 compared with a narrative fair value of $18.50, the most followed view sees Viatris trading at a meaningful discount that hinges on how effectively the company shifts its product and margin mix.

The company is well-positioned to benefit from sustained demand growth due to global population aging and increasing chronic disease prevalence, as demonstrated by positive late-stage pipeline developments in chronic disease, pain, and ophthalmology, which is setting the stage for long-term revenue growth through new branded and generic launches in large, underserved markets.

Want to understand what underpins that higher fair value for Viatris? The narrative leans on measured revenue expansion, a step change in profitability and a richer product mix. Curious which financial swing factors are doing the heavy lifting in the model? The full narrative lays out the specific growth, margin and valuation assumptions that connect today’s price to that $18.50 figure.

Result: Fair Value of $18.50 (UNDERVALUED)

However, Viatris still faces pressure from generic price competition and regulatory scrutiny, and any setbacks on product approvals could quickly challenge that 12.3% undervalued narrative.

Next Steps

With both optimism and caution running through the Viatris story, this is a useful moment to review the numbers yourself and act on your own judgment. A quick way to frame that view is to weigh the 3 key rewards and 1 important warning sign

Looking for more Viatris sized investment ideas?

If you are serious about building a stronger portfolio, do not stop at Viatris. Use the Simply Wall Street Screener to uncover other focused opportunities before the crowd catches on.

• Target reliable cash generators by scanning for companies with strong finances using the solid balance sheet and fundamentals stocks screener (50 results).
• Spot potential mispricings early when you search for quality companies trading below intrinsic value through the 50 high quality undervalued stocks.
• Strengthen your income stream by hunting for established payers with the 10 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.